Gut feeling: MicroRNA discriminators of the intestinal TLR9–cholinergic links  by Nadorp, Bettina & Soreq, Hermona
International Immunopharmacology 29 (2015) 8–14
Contents lists available at ScienceDirect
International Immunopharmacology
j ourna l homepage: www.e lsev ie r .com/ locate / in t impGut feeling: MicroRNA discriminators of the intestinal TLR9–cholinergic linksBettina Nadorp a,b,c,d, Hermona Soreq a,b,c,⁎
a Department of Biological Chemistry, The Hebrew University of Jerusalem, Israel
b Institute of Life Sciences, The Hebrew University of Jerusalem, Israel
c Edmond and Lily Safra Center of Brain Science, The Hebrew University of Jerusalem, Israel
d Grass Center for Bioengineering, The Hebrew University of Jerusalem, Israel⁎ Corresponding author at: Department of Biological Ch
of Jerusalem, Jerusalem 91904, Israel. Tel.: +972 2 65851
E-mail address: hermona.soreq@mail.huji.ac.il (H. Sor
http://dx.doi.org/10.1016/j.intimp.2015.04.058
1567-5769/© 2015 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 28 January 2015
Received in revised form 14 April 2015
Accepted 15 April 2015
Available online 20 May 2015
Keywords:
Acetylcholinesterase
Butyrylcholinesterase
Intestinal inﬂammation
MicroRNA
Non-neuronal acetylcholine
Toll-Like Receptor 9The intestinal tissue notably responds to stressful, cholinergic and innate immune signals bymicroRNA (miRNA)
changes, but whether and how those miRNA regulators modify the intestinal cholinergic and innate immune
pathways remained unexplored. Here, we report changes in several miRNA regulators of cholinesterases
(ChEs) and correspondingly modiﬁed ChE activities in intestine, splenocytes and the circulation of mice exposed
to both stress and canonical or alternative Toll-Like Receptor 9 (TLR9) oligonucleotide (ODN) aptamer activators
or blockers. Stressful intraperitoneal injection of saline, the anti-inﬂammatory TLR9 agonist mEN101 aptamer or
the inﬂammation-activating TLR9 aptamer ODN 1826 all increased the expression of the acetylcholinesterase
(AChE)-targeting miR-132. In comparison, mEN101 but neither ODN 1826 nor saline injections elevated intesti-
nal miR-129-5p, miR-186 andmiR-200c, all predicted to target both AChE and the homologous enzyme butyryl-
cholinesterase (BChE). In cultured immune cells, BL-7040, the human counterpart of mEN101, reduced AChE
activity reﬂecting inﬂammatory reactions in amanner preventable by the TLR9 blocking ODN2088. Furthermore,
the anti-inﬂammatory BL-7040 TLR9 aptamer caused reduction in nitric oxide and AChE activity in both murine
splenocytes and human mononuclear cells at molar concentrations four orders of magnitude lower than ODN
1826. Our ﬁndings demonstrate differential reaction of cholinesterase-targeting miRNAs to distinct TLR9
challenges, indicating upstreammiRNA co-regulation of the intestinal alternative NFκB pathway and cholinergic
signaling. TLR9 aptamers may hence potentiate miRNA regulation that enhances cholinergic signaling and the
resolution of inﬂammation, which opens new venues for manipulating bowel diseases.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Intestinal inﬂammation is a common physiological response to
infection, tissue damage or stress. Homeostasis is restoredwhen inﬂam-
mation is restricted in time and space, but chronic inﬂammation can
trigger autoimmunity diseases, tissue damage and cancer [1]. Speciﬁcal-
ly, inﬂammatory bowel disease (IBD) is a condition caused by chronic/
persistent intestinal inﬂammation. The hallmarks of IBD include elevat-
ed levels of intestinal pro-inﬂammatory cytokines, disruption of the gut
tissue and severe clinical symptoms. Recent expansion of immunologi-
cal research describes the role of cholinergic signaling pathways [2]
and of the pattern-recognition, innate immunity receptors, called toll-
like receptors (TLRs), in intestinal inﬂammation [3]. Both of these path-
ways involve hierarchically high signaling regulators that communicate
with each other to control inﬂammatory reactions. However, the under-
lying molecular mechanisms regulating this communication between
the cholinergic and TLR pathways remained incompletely understood.emistry, The HebrewUniversity
09.
eq).
. This is an open access article underThe different TLRs, expressed by macrophages, dendritic cells and B
cells, are distinguished by their speciﬁc ligands. For example, TLR4, the
most extensively studied TLR, is known to react to the gram-negative
bacterial cell wall component lipopolysaccharide (LPS) and initiates
the NFκB cascade [3]. TLR9, on the other hand, is a sensor of bacterial
DNA with un-methylated CpG motifs [4] that plays a role in multiple
autoimmune disorders [5] as well as in intestinal immune tolerance
[6]. Unlike most TLRs, which are trans-membrane proteins, TLR9 is
primarily expressed in endosomes. Twomain types of CpG oligonucleo-
tides (ODNs), type A and B can activate TLR9 by initiating distinct
signaling cascades [7]. Brieﬂy, CpG Type A activates the adapter protein
MyD88, initiating the transcription factor interferon regulatory factor 7
(IRF7). Activated IRF7 translocates to the nucleus and induces the
expression of interferon-α (INF-α) [8] through I kappa B kinase α
(IKKα). CpG Type B also activates MyD88, which then phosphorylates
the kinase IKKβ, within its complex with IKKα. Once phosphorylated,
IKKβ phosphorylates the protein IkB, bound to the p65/p50 dimer of
the NFκB family transcription factors, and prevents their nuclear trans-
location. Following IkB degradation, the dimer is free to translocate to
the nucleus and induce expression of the pro-inﬂammatory cytokines
interleukin (IL)-1β, IL-6 and TNF-α and the inducible nitric oxidethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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is called the ‘canonic’ or pro-inﬂammatory NFκB pathway [3].
Over the last decade, a second, alternative pathway was discovered,
in which MyD88 is not involved. Instead, NFκB-inducing kinase [9] is
phosphorylated, which in turn phosphorylates IKKα alone [10]. Phos-
phorylated IKKα cleaves another dimer of the NFκB family protein,
p100/RelB, into p52/RelB [11–13]. Then, p52/RelB can translocate to
the nucleus and induce the expression of other proteins, like the acetyl-
choline hydrolyzing enzyme acetylcholinesterase [14,15] and the
immune regulatory enzyme indoleamine 2, 3-dioxygenase [15,16].
The alternative pathway can be activated by several known ligands,
such as cluster of differentiation 40 ligand (CD40L) [10]. Certain TLR9 li-
gands can also activate this anti-inﬂammatory pathway [17], suggesting
that TLR9 may function in a MyD88-unrelated manner.
Importantly, NFκB also serves additional receptors, e.g. the nicotinic
acetylcholine receptor (nAChR), suggesting intricate inter-related control
over the canonical and anti-inﬂammatory TLR9 pathways. For example,
α7 nAChR signaling can restrict intestinal inﬂammation by activating the
JAK2–STAT3 cascade and promoting secretion of the anti-inﬂammatory
cytokine IL-10 [2]. Further, acute activation of the canonical NFκBpathway
is followed by rapid over-expression of AChE messenger RNA (mRNA)
[18] via the NFκB recognition motif in the AChE promoter or due to
epigenetic regulation [19,20]. Correspondingly, the cholinergic–TLR9
interaction was recently shown to modulate circulation cytokines [21].
The brain restricts inﬂammation and prevents sepsis through ACh
released from efferent vagus nerve ﬁbers, and ACh binds α7 nAChR
on macrophages and dendritic cells, blocking NFκB function [22]. Hy-
drolysis of ACh by AChE and BChE [23] can induce overproduction of
pro-inﬂammatory cytokines [15]. Pattern recognition of bacterial CpG
DNAmotifs by TLR9 is instrumental both inmaintaining the persistence
and inducing the resolution of inﬂammation. Stimulating TLR9-
expressing dendritic cells in the intestinal lamina propria (LpDC)
with CpG DNA disrupts intestinal homeostasis by recruiting pro-
inﬂammatory T helper cells (Th1 and Th17) [24].
At the post-transcriptional level, both TLR and cholinergic signaling
processes are subjected to microRNA (miRNA) regulation. MiRNAs are
small, non-coding RNAs that regulate mRNA post-transcriptionally by
limiting their translation and inducing their degradation [25]. Each
miRNA targets many different transcripts, which often participate in
the same biological pathway. We have recently identiﬁed the subclass
of CholinomiRs: miRNAs predicted to target the inﬂammation-
suppressive cholinergic signaling pathway [26]. Those include the
AChE-targeting miR-132, increases in which elevate cholinergic signal-
ing and limit peripheral and intestinal cytokine production [18]. But the
response of CholinomiRs to TLR9 manipulations remained unknown.
To approach this question, we used BL-7040, an AChE mRNA-
targeting antisense oligonucleotide that suppresses AChE mRNA levels,
thereby elevating ACh and alleviating inﬂammation [14,27,28]. BL-7040
reduced serum AChE activity in mice, whichmay potentiate the cholin-
ergic anti-inﬂammatory effect [29]. Therefore, we predicted that
CholinomiR suppression of circulation AChE could cause such anti-
inﬂammatory consequences. However, the BL-7040 reaction was
prevented by the TLR9 inhibiting oligonucleotide ODN 2088 and was
not mimicked by the inﬂammation inducing ODN 1826 [29], suggesting
that the mechanism involved anti-inﬂammatory activation of TLR9. To
investigate the interaction between the intestinal cholinergic and innate
immune pathways, and to explore the potential links between those
pathways and TLR9, we tested CholinomiRmodulations under different
TLR9-modifying ODNs in intestinal inﬂammation.
2. Material & methods
2.1. Animal experiments
Animal experiments were performed in accordancewith The Hebrew
University's animal procedures (Ethics number of research: NS-10205-4).2.2. Intestinal sections
We exposedmale C57/B6J mice to predator scent and injected them
intra-peritoneally on four consecutive days with different ODN's
(mEN101, ODN 1826, ODN 2088, 500 μg/kg) or saline, essentially as in
[21]. Oligonucleotides used were:
1. mEN101, murine anti-inﬂammatory TLR9 activator:
5′-CTG CAA TAT TTT CTT GCA metCmetCmet-3′
2. ODN 1826, a pro-inﬂammatory CpG type B TLR9 activator:
5′-TCC ATG ACsGs TTC CTG ACsGs TT-3′
3. ODN 2088, a TLR9 blocking aptamer
5′-TsCsCs TsGsGs CsGsGs AsGs Ts-3′
Non-injected mice served as controls. 7 days later, we removed
intestinal sections from mice of all groups as in [18]. The mice were
housed four per cage, at 21 ± 1 °C, in a 12-h light/dark cycle.
2.3. In vitro procedures
Murine mononuclear splenocytes were isolated using lympho-
cyte separation medium (Mediatech Inc.) and cultured in complete
RPMI medium (supplemented with 10% fetal bovine serum,
200 mM L-glutamine, 10,000-U/ml penicillin and streptomycin,
50 μM 2-β-mercaptoethanol) in 48 well plates, 0.5 million cells
per well. Cells were challenged with BL-7040 (0–10 μM) in the pres-
ence or absence of the TLR9 blocker ODN 2088 (0.1 μM). Additional
oligonucleotides used:
4. BL-7040 (2′O-methyl), an anti-inﬂammatory TLR9 activator:
5′-CTG CCA CGT TCT CCT GCA metCmetCmet-3′
5. ODN 1585, a pro-inﬂammatory CpG type A TLR9 activator:
5′GsGsGGTCAACGTTGAGsGsGsGsGsGs-3'
24 h post-challenge, media and cells were collected.
2.4. Primary human blood mononuclear cells (PBMCs)
Primary human blood mononuclear cells (PBMCs) were obtained
and cultured as previously described in [18]. AChE activity in human
mononuclear cells was measured 24 h after treatment with 0.01 μM
BL-7040 or 0.1 μM of CpG B (ODN 1826), CpG A (ODN 1585) or TLR9
Inhibitor (ODN 2088).
2.5. Nitric oxide measurements
Nitric oxide measurements involved the Griess method [30]. NO
levels were determined in conditioned medium from the murine mac-
rophage cell line RAW264.7 cultures. 100 μl of each sample + 100 μl
of Griess reagent (1% sulfanilamide/0.1% naphthylethylenediamine
dihydrochloride/2.5% H3PO4) were incubated for 10–20 min at room
temperature. Absorbance was read at 546 nm in a micro-ELISA reader
[31].
2.6. Cholinesterase catalytic activity measurements
AChE activity levels were assessed by measuring hydrolysis rates
of 1 mM acetylthiocholine (ATCh, Sigma), as described previously
[32], following 20 min incubation with and without 5 × 10−5 M
tetraisopropyl pyrophosphoramide (iso-OMPA, Sigma), a speciﬁc
BChE inhibitor, to assay for AChE-speciﬁc or total cholinesterase
activity. Each sample was assayed in n = 3 or more.
2.7. qRT-PCR
Isolation of small and total RNA from splenocytes or intestinal
sections was carried out with the miRNeasy Mini Kit (QIAGEN).
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quantitative real-time PCR using the PerfeCTa® microRNA Assay
(Quanta). Expression levels were normalized to endogenousexpression of U6 snRNA. Fold change values were calculated
using the ΔΔCt method.2.8. Bioinformatic analysis
Bioinformatic analysis of microRNA-target binding energies was
conducted using the RNAhybrid algorithm, version 2.2 (http://
bibiserv.techfak.uni-bielefeld.de/rnahybrid/).2.9. Statistical analysis
Collected data was summarized and displayed as mean ± standard
error of mean using the SPSS software (version 19.0, SPSS INC, Chicago,
IL, USA). The statistical analysis was performed using Mann–Whitney's
U-test or One-way ANOVA and Bonferroni post-hoc test, whereα b 0.05
was considered signiﬁcant.3. Results
3.1. TLR9 ODNs induce CholinomiR changes in mouse intestinal sections
Our working hypothesis predicted that AChE overexpression
enhances the inﬂammatory output, whereas AChE decreases reﬂect
anti-inﬂammatory states [33]. To test this hypothesis, we prepared in-
testinal sections from untreated control mice and from mice subjected
to stress following intra-peritoneal injections of saline or of mEN101,
an activator of the anti-inﬂammatory TLR9 reaction, or ODN 1826, a
pro-inﬂammatory Type B activator of NFκB. We extracted RNA and
determined the levels of four CholinomiRs by qRT-PCR. All of the tested
CholinomiRs were predicted to target the transcript encoding for the
circulation soluble AChE-R [23,26]. One CholinomiR, miR-132 was
validated to also target the ‘synaptic’ AChE-S transcript [18]. The other
three CholinomiRs, miR-129-5p, miR-186 andmiR-200c are all predict-
ed to target both the soluble alternative splicing variant AChE-R and
BChE in the circulation (Fig. 1A). Interestingly, the calculated binding
energies of these three miRNAs (miR-129-5p, miR-186 and miR-200c)
towards their AChE-R and BChE targets showed preferred binding to-
wards BChE;−17.1 kcal/mol,−16 kcal/mol,−15.6 kcal/mol; in com-
parison to −13.5 kcal/mol, −11.6 kcal/mol or −10.6 kcal/mol,
−11.8 kcal/mol towards AChE-R, respectively (Fig. 1B). Of note, the
intestinal miR-132 levels were increased under both saline and ODN
1826 stresses. In comparison, none of the other CholinomiRs showed
changes following saline injection. However, all of them presented
increased intestinal levels under the anti-inﬂammatory mEN101 treat-
ment, but not under the NFκB-stimulating ODN 1826 (Fig. 1B). The
extent of the observed increases did not reﬂect the number of miRNA-
binding elements on the targeted transcript, such that miR-186, with a
total of 3 binding elements on AChE-R and BChE showed a similar
change to that of miR-200c with only two sites (Fig. 1B).Fig. 1. TLR9 aptamers induce differential changes in intestinal miRNA controllers of
Cholinesterases. A. To test the TLR9 effects on CholinomiRs targeting two cholinesterase
variants, intestinal sections were prepared from mice exposed to 500 μg/kg of the NFκB
stimulating ODN 1826 (red), to the anti-inﬂammatory TLR9 stimulating oligonucleotide
mEN101 (blue) or saline (green), to control for the stress impact. The sequences of tested
CholinomiRs [26] are shown; all of them are predicted to target AChE-R and either AChE-S
or BChE. B. Seven days after exposure, qRT-PCR measurements quantiﬁed the intestinal
levels of the AChE-S and AChE-R targeting CholinomiR-132 as well as miR-129-5p,
−186 or −200c, all of which are predicted to target both AChE-R and BChE. The bar
graphs show ΔΔCt values normalized to snRNA U6 (white: control; green: saline; blue:
mEN101; red: ODN1826). Bonferroni corrected p-values are noted above. Note mEN101
induced increases in all of the AChE-R and BChE-targeting miRNAs, but not in miR-132.
MiRNA-target binding structures (miRNA sequence: red, target mRNA sequence: green)
binding energies in kcal/mol are shown. The binding energies of miR-132 towards the
two AChE variants are equal, whereas the other three CholinomiRs show lower binding
energies towards BChE.
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splenocytes
Pro-inﬂammatory NFκB activation leads to increases in circulation
AChE levels under diverse inﬂammation and post-traumatic states [21,
29,34]. In contrast, mild alternative activation of NFκB via anti-
inﬂammatory TLR9 signaling leads to down-regulation of AChE activity,
resolution of inﬂammation and restored homeostasis. Based on these
considerations, the anti-inﬂammatory effects of the tested oligonucleo-
tides could be mediated by TLR9 induction. However, the BL-7040
sequence was initially designed as an antisense to human AChE. This
primarily implied that BL-7040 could potentially function in twoFig. 2. BL-7040 induces a decrease in murine AChE activity through low afﬁnity TLR9 activation
(m) AChE (orange) and BL-7040 (blue). Mismatches are portrayed in red. B. AChE activity inm
(0.1 μM). C. Nitrite production in RAW264.7macrophages following exposure to 0.01 μMBL-70
effects (molar ratio of ODN 2088/agonist shown). * indicates p-value b 0.05 using Mann–Whitpathways. Molecular modeling indicated that BL-7040 could not
function as an antisense agent in mice due to 4 mismatches in its 20-
nucleotides long sequence, which prevents interaction with its murine
mRNA target (Fig. 2A). In spite of this difference, BL-7040was able to re-
duce AChE activity levels by 50% in murine splenocytes (Fig. 2B), the
same reduction seen following treatment with CD40L, an alternative
NFκB pathway activator [29]. Moreover, this reduction was completely
abolished under co-treatment with the TLR9 inhibitor ODN 2088, dem-
onstrating that BL-7040 suppresses AChE through a TLR9-mediated,
alternative NFκB mechanism. Competition assay using ODN 2088 as a
TLR9 inhibitor in the murine macrophage cell line RAW264.7 showed
that BL-7040 is a low afﬁnity ligand of TLR9; ligand/inhibitor ratio of. A. Molecular modeling of complexes between the second exon of human (h) and mouse
urine splenocytes 24 h after treatment with BL-7040 (0.01 μM)with or without ODN 2088
40 or 0.1 μMODN 1826, concomitantly with increasing doses of ODN 2088 that block their
ney's U-test.
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whereas ligand/inhibitor ratio of 1:100 was sufﬁcient to suppress
activation by the pro-inﬂammatory ODN 1826 (Fig. 2C).
3.3. TLR9 activation suppresses AChE activity in murine splenocytes and
human mononuclear cells
Next, we tested the inﬂammation-regulating effects of the three
types of immune-stimulatory CpG ODNs as sub-classiﬁed by their dis-
tinct effects on leukocytes: CpG type A ODNs promote a strong produc-
tion of interferons (IFNs) in dendritic cells via the interferon responding
factor (IRF) transcription complex; CpG type B ODNs induce both AP-1
and NFκB-mediated transcription, which promotes B cell survival and
production of pro-inﬂammatorymediators; and CpG type C ODNs com-
promise both activities. At the structural level, CpG type A and B ODNs
are typically monomeric, but CpG type C ODNs act as dimers [21,29].
Murine splenocytes treated with low dose CpG-B ODN 1826 showed
ca. 50% reduction in AChE activity, similar to that seen following treat-
ment with CD40L (Fig. 3A). CpG-A ODN 1585 and the TLR9 antagonist
ODN 2088 failed to induce such reductions. In comparison, primary
human blood mononuclear cells (PBMCs) reacted to BL-7040 as well
as to ODN 1826 by less pronounced, albeit signiﬁcant reduction in
AChE activity, whereas the CpG A ODN 1585 or the TLR9 inhibitor
ODN treatment failed to change AChE activities in PBMCs (Fig. 3B).
Taken together, these ﬁndings show that anti-inﬂammatory activation
of TLR9, as opposed to its pro-inﬂammatory activation, may induce a
delayed suppression of inﬂammatory response in circulation immune
cells.
4. Discussion
TLR9-mediated signaling possesses a yet unknown duality with
regard to the inﬂammatory process. Namely, it participates in both the
breakdown and the maintenance of immune tolerance; and it can
propagate or restrict inﬂammation. Our ﬁndings suggest that both
upstream miRNA regulation and downstream signaling pathways to
TLR9 determine pro- and anti-inﬂammatory intestinal activities. Specif-
ically, we show that BL-7040, a synthetic, weak-binding TLR9-speciﬁc
aptamer, triggers miRNA changes supporting the non-canonical path-
way of NFκB activation, and that ex-vivo, BL-7040 proved effective in
diminishing inﬂammation in murine splenocytes and PBMCs.Fig. 3.Anti-inﬂammatory TLR9-mediated response induces a decline of AChEactivity inmurine s
1 μg/ml CD40L or 0.01 μMof ODN 1826 show ~50% reduction in AChE activity. B. AChE activity i
(ODN 1826), CpG A (ODN 1585) or TLR9 Inhibitor (ODN 2088), n = 3. * indicates p-value b 0.Our results suggest a miRNA-mediated mechanism initiating an
anti-inﬂammatory, homeostatic TLR9 signaling that suppresses intesti-
nal and immune cell inﬂammation via cholinergic blockade. Intriguing-
ly, this response associates with increases in three dual targeting
CholinomiRs that share sequence complementarity with the two solu-
ble cholinesterases in the circulation, AChE-R and BChE: miR-129-5p,
miR-186 and miR-200c. Of those, miR-200c is known to be increased
in blood of Crohn's disease patients [9], which supports our results. In
contrast, miR-132, which targets AChE-R and AChE-S, but not BChE,
showed increased levels in intestinal sections following injection of
the pro-inﬂammatory CpG A ODN 1826 as well as of saline, suggesting
relevance for both psychological stress and inﬂammation. This is sup-
ported by increased levels of miR-132 in intestinal explants removed
from human IBD patients during surgery [35]. The minimal binding en-
ergies with BChE of the three CholinomiRs targeting the soluble ChEs
are lower than those towards AChE-R, indicating preferential binding
of BChE. This might further explain the different changes in the levels
of these miRNAs following ODN treatments in comparison to those of
miR-132. Notably, miR-132 shows equal binding energies towards the
soluble AChE-R and the synaptic AChE-S variant, but fails to target
BChE. Differences between the reactions of these CholinomiRs to
diverse TLR9 modulators could indicate distinct roles for the two circu-
lating cholinesterases in inﬂammatory states. Supporting this notion,
the amount of BChE in the circulation is much higher than that of
AChE and mutation-induced impairments in the capacity of BChE to
hydrolyze ACh associate with acute responses to anti-cholinesterase
treatment or exposure [36,37].
The ability of TLR9-expressing innate immune cells to respond to
pathogenic DNA, while ignoring self-originated DNA or DNA from
harmless bacteria requires tight regulation. Our ﬁndings indicate that
upstream CholinomiR regulation modulates the cholinergic anti-
inﬂammatory reﬂex, known to attenuate cytokine production in innate
immunity cells. This mechanism might play a role in the response to
weak binding of “benign” DNA motifs to TLR9. Such binding induces
non-canonical activation of NFκB and therefore restricts an inﬂammato-
ry response. The efﬁcacy of BL-7040 as a prospective oral treatment for
Myasthenia gravis (MG) has been described previously [38,39]. BL-7040
was mainly accounted for as an AChE-R suppressing aptamer in vivo,
but our current observations expand this concept towards miRNA
regulation and non-canonical NFκB activation. MG is an autoimmune
disorder involving production of antibodies against the α7 nAChR,plenocytes and humanmononuclear cells. A.Murine splenocytes 24h after treatmentwith
n humanmononuclear cells, 24 h after treatment with 0.01 μMBL-7040 or 0.1 μMof CpG B
05 using Mann–Whitney's U-test.
Fig. 4. Oligonucleotide discriminators of the TLR9-cholinergic links. Left: miRNA regulators suppress the production of AChE and BChE, thus modifying ACh levels and regulating the
cholinergic anti-inﬂammatory blockade of the NfκB pathway through the α7 nAChR. Right: Both CpG type B oligonucleotides and the BL-7040 TLR9 aptamer can activate inﬂammatory
modifying responses, whereas the blocking aptamer ODN 2088 prevents TLR9 signaling to the NfκB pathway. Bottom: The canonical activation mode is pro-inﬂammatory (marked red),
whereas the alternative mode is anti-inﬂammatory (marked blue) and induces immunosuppression, while at the same time suppressing AChE activity, increasing ACh levels and
potentiating the cholinergic anti-inﬂammatory response.
13B. Nadorp, H. Soreq / International Immunopharmacology 29 (2015) 8–14which results in a reduced capacity of theα7 nAChR to block inﬂamma-
tion in pro-inﬂammatory signaling. In contrast, BL-7040 treatment of
murine splenocytes reduced both NO and AChE, indicating a concerted
anti-inﬂammatory effect. Given that ODN 2088 may block much of BL-
7040's activity, these ﬁndings suggest that BL-7040 acts primarily as a
weak TLR9 agonist, whichmight account for its notable lack of choliner-
gic side effects in therapy.
In conclusion, we propose that miRNA regulators suppress the
production of AChE and BChE in peripheral blood leukocytes and the
circulation, thus modifying ACh levels and regulating cholinergic anti-
inﬂammatory blockade of the NFκB pathway through the α7 nAChR.
Both CpG type B oligonucleotides and the BL-7040 TLR9 aptamer can
activate inﬂammatory modifying responses, whereas the blocking
aptamer ODN 2088 prevents TLR9 signaling through the NfκB pathway.
Fig. 4 presents this concept schematically, with the pro-inﬂammatory
and anti-inﬂammatory reactions color-coded (red and blue, respective-
ly). The canonical activation mode is pro-inﬂammatory, whereas the
alternative mode is anti-inﬂammatory and induces self-created
immunosuppression, while simultaneously suppressing AChE activity.
This increases ACh levels and potentiates the cholinergic anti-
inﬂammatory response. Our ﬁndings hence demonstrate differential
reaction of cholinesterase-targeting miRNAs to distinct TLR9 changes;
indicating co-regulation of the intestinal alternative NFκB pathway
and cholinergic signaling. We further show that ODN aptamers of
TLR9 may potentiate miRNA regulation that enhances cholinergic
signaling, leading to resolution of inﬂammation. This may open new
ways for manipulating bowel diseases, especially IBD.Acknowledgments
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